BioLife Solutions (BLFS)
(Real Time Quote from BATS)
$22.54 USD
+0.49 (2.22%)
Updated Aug 8, 2024 03:55 PM ET
After-Market: $22.79 +0.25 (1.11%) 4:18 PM ET
4-Sell of 5 4
F Value C Growth C Momentum D VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$22.54 USD
+0.49 (2.22%)
Updated Aug 8, 2024 03:55 PM ET
After-Market: $22.79 +0.25 (1.11%) 4:18 PM ET
4-Sell of 5 4
F Value C Growth C Momentum D VGM
Zacks News
3 Soaring MedTech Stocks That Might Lose Ground in 2021
by Trina Mukherjee
Despite MedTech industry's bright prospects in 2021, investors should be wary of stocks like BLFS, STAA and TGTX, given their unfavorable Zacks Rank and weak fundamentals.
Should You Buy BioLife (BLFS) Ahead of Earnings?
by Zacks Equity Research
BioLife (BLFS) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Moving Average Crossover Alert: BioLife Solutions
by Zacks Equity Research
BioLife Solutions, Inc. (BLFS) is looking like an interesting pick from a technical perspective, as the company is seeing favorable trends on the moving average crossover front.
BioLife (BLFS) Catches Eye: Stock Jumps 12.1%
by Zacks Equity Research
BioLife (BLFS) saw a big move last session, as its shares jumped more than 12% on the day, amid huge volumes.
CytoDyn (CYDY) to Report Q4 Earnings: What's in the Cards?
by Zacks Equity Research
On CytoDyn's (CYDY) upcoming earnings call, investor focus will be on the updates related to its CCR5 antagonist candidate, leronlimab, which is being developed for multiple therapeutic indications.
Why Earnings Season Could Be Great for BioLife Solutions (BLFS)
by Zacks Equity Research
BioLife Solutions (BLFS) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Aurora Cannabis (ACB) to Report Q3 Earnings: What's in Store?
by Zacks Equity Research
Aurora Cannabis' (ACB) fiscal third-quarter results likely to reflect solid prospects in the Canadian market.
What's in the Cards for SmileDirectClub's (SDC) Q1 Earnings?
by Zacks Equity Research
SmileDirectClub's (SDC) first-quarter performance is likely to reflect benefits from international presence and product development.
Daqo New Energy (DQ) to Post Q4 Earnings: What's in Store?
by Zacks Equity Research
Our proven model does not conclusively predict an earnings beat for Daqo New Energy (DQ) this season.
Medical Products Industry Outlook: Prospects Seem Promising
by Trina Mukherjee
Growth prospects look bright for the Zacks Medical Products industry, thanks to AI, Medical Mechatronics and Robotics and rampant M&As.
BioLife Solutions (BLFS) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
by Zacks Equity Research
BioLife (BLFS) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
BioLife Solutions (BLFS) to Report Q1 Results: Wall Street Expects Earnings Growth
by Zacks Equity Research
BioLife (BLFS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Here's Why You Should Invest in Stryker (SYK) Stock Right Now
by Zacks Equity Research
Stryker's (SYK) strong guidance for the first quarter of 2019 buoys optimism in the stock.
Medical Products Industry Gathering Steam: 3 Stocks to Buy
by Nabaparna Bhattacharya
The Medical Products market is gaining traction from a firm exposure to robotics, medical mechatronics and the bipartisan two-year suspension of a 2.3% excise tax on MedTech manufacturers.
BioLife (BLFS) to Report Q3 Earnings: What's in the Cards?
by Zacks Equity Research
BioLife (BLFS) is likely to gain from solid segmental revenues in Q3.
What's in Store for AmerisourceBergen (ABC) in Q4 Earnings?
by Zacks Equity Research
AmerisourceBergen's (ABC) fiscal fourth-quarter results are likely to be driven by its core Pharmaceutical Distribution business despite a competitive industry.
What's in Store for Quidel (QDEL) This Earnings Season?
by Zacks Equity Research
Strong growth in Cardiac Immunoassay segment's revenues is likely to drive Quidel's (QDEL) top line in Q3.
Can Solid European Sales Boost Inogen (INGN) in Q3 Earnings?
by Zacks Equity Research
Strong performance in Europe is likely to boost Inogen's (INGN) top line in the third quarter. However, the decline in rental revenues is a concern.
BioLife Solutions (BLFS) Reports Next Week: Wall Street Expects Earnings Growth
by Zacks Equity Research
BioLife (BLFS) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
BioLife Solutions Sees Hammer Chart Pattern: Time to Buy?
by Zacks Equity Research
BioLife Solutions has been struggling lately, but the selling pressure may be coming to an end soon.
Is BioLife Solutions (BLFS) Stock Outpacing Its Medical Peers This Year?
by Zacks Equity Research
Is (BLFS) Outperforming Other Medical Stocks This Year?
The Zacks Analyst Blog Highlights: Turtle Beach, BioLife Solutions, IntriCon and Medifast
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Turtle Beach, BioLife Solutions, IntriCon and Medifast
Trump's Approval Rating Buoy Wall Street: 4 Top Gainers
by Nitish Marwah
Trump's pro-growth agenda has worked wonders for the economy as a whole.
Canopy Growth (CGC) Jumps: Stock Rises 7.4%
by Zacks Equity Research
Canopy Growth (CGC) saw a big move last session, as its shares jumped more than 7% on the day, amid huge volumes.
Bull Run to Continue in Rest of 2018: 5 Terrific Growth Picks
by Nalak Das
Strong economic fundamentals of the United States suggest that the recent volatility may be transitory and that markets will continue their uptrend.